CHINO HILLS, CALIFORNIA — November 4, 2025 — Leads & Copy — SOHM, Inc. (OTCID:SHMN) is pleased to acknowledge recent FDA commentary and industry analyses signaling continued evolution of regulatory pathways for genome-editing technologies.
The pharmaceutical and biotechnology company, specializing in generic drugs and gene-editing tools, is a leader in Gene Editing and Cell Engineering. Recent FDA commentary and industry analyses signal a continued evolution of regulatory pathways for genome-editing technologies. These developments highlight increasing regulatory focus on precision-engineered genetic tools, non-viral delivery approaches, and scalable manufacturing frameworks.
SOHM is advancing its proprietary ABBIE™ genome-engineering platform, which is designed to enable DNA-insertion events through a programmable enzyme architecture. ABBIE is currently in preclinical development.
David Aguilar, COO of SOHM, noted that as regulatory frameworks evolve, emphasis continues to be placed on genomic safety, process control, and manufacturing rigor. Aguilar added that ABBIE was designed to support controlled genomic engineering without the use of viral vectors, and preclinical work continues to focus on establishing safety, mechanism, and reproducibility.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Source: SOHM, Inc
